Načítá se...
Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...
Uloženo v:
| Vydáno v: | Respirol Case Rep |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412970/ https://ncbi.nlm.nih.gov/pubmed/28469919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.241 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|